In contrast to normal healthy cells, however, NRF2-dependent induction of these transporters causes drug resistance in cancer cells, suggesting a negative role of NRF2 in clinical cancer chemotherapy, as discussed below. This evidence concerns the gene NFE2L2 and cancer.